Early-stage funding for European life sciences companies

We are a venture capital firm specialised in seed investment for innovative early stage European companies.

Our current portfolio comprises biotech, medtech and diagnostics companies, all working to develop truly disruptive solutions for high unmet medical needs.

Dezima and Acerta, multi-billion Euro success stories

BioGeneration was co-founder and investor in two of the most successful biotech startups in Europe: Acerta Pharma and Dezima Pharma. Acerta Pharma develops a new drug for the treatment of hematologic malignancies (leukemia) and was sold to AstraZeneca for up to US$ 7 billion. Dezima Pharma is developing a treatment for of a cardiovascular disorder (dyslipidemia) and was sold to Amgen for a deal amount of up to US$ 1.5 billion.

Shaping new life-science ventures

Our varied and complementary experience has been gained from working within small and large pharma and biotech companies. Based on this experience and through our extensive industry network, we are able to bring a range of sector-relevant expertise to help accelerate product development and shape the companies to become attractive investment opportunities for the industry.

Latest news

Synaffix Announces License Agreement with Mersana Therapeutics for the Use of its GlycoConnect™ Site-Specific ADC Technology

Jan 4, 2019

AMSTERDAM, NETHERLANDS – January 4, 2019 – Synaffix B.V. announced today it has entered into a license agreement with Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates...

BioGeneration Ventures’ portfolio company Staten Biotechnology announces collaboration with Novo Nordisk

Dec 17, 2018

BioGeneration Ventures (BGV) is pleased to announce that its portfolio company Staten Biotechnology B.V. and Novo Nordisk A/S have entered into a collaboration and exclusive option agreement. Under the collaboration agreement, Staten will continue to develop its lead...

Press Release NorthSea Therapeutics: Icosabutate latest data shows direct and potent anti-fibrotic effect in both differentiated rodent NASH models and human stellate cells.

Nov 9, 2018

Results to be presented at the AASLD congress 2018, 9-13 November In a biopsy-confirmed fibrotic ob/ob NASH mouse model, icosabutate reduced hepatic fibrosis in association with a 45% decrease in myofibroblast content in pre- versus post-treatment liver biopsies In a...

Dr. Axel Mescheder appointed CEO of Cristal Therapeutics as focus intensifies on proprietary oncology nanomedicine pipeline

Nov 2, 2018

Maastricht, The Netherlands, 2nd November 2018 – Cristal Therapeutics, a clinical stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, has appointed Dr. Axel Mescheder to the role...

News overview

Next events

Innovation for Health – Feb 14th

Jan 16, 2019

Edward will attend the Innovation for Health conference 2019 in Rotterdam. You can reach out to us by email to set up a meeting or request one in the Biotech Showcase partnering program.

Event overview

Latest investments

Portfolio